Anitocabtagene autoleucel is under clinical development by Arcellx and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData, Phase III drugs for Relapsed Multiple Myeloma have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Anitocabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anitocabtagene autoleucel overview
Anitocabtagene autoleucel is under development for the treatment of relapsed or refractory multiple myeloma and myasthenia gravis. The immune cell therapy consists of Antigen Receptor Complex T cells (ARC-T) T containing a novel synthetic protein1,2 binding domain (non-scFv) that kills the tumor cells. It acts by targeting cells expressing BCMA. It is administered through intravenous route.
Arcellx overview
Arcellx is a clinical-stage biotechnology company that develops immunotherapies for cancer treatments. The company utilizes its proprietary therapeutic platforms, ddCAR and ARC-SparX for drug development. Its lead product candidate anitocabtagene autoleuce (anito-cel), is at phase 2 pivotal trial, for the treatment of relapsed and refractory multiple myeloma. Arcellx pipeline includes drugs for treatments of multiple myeloma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), hepatocellular carcinoma, and small cell lung cancer. The company operates with an additional office in Rockville, Maryland, the US. Arcellx is headquartered in Redwood City, California, the US.
For a complete picture of Anitocabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
